1
|
Yu TM, Sun CS, Lin CL, Wang CY, Chang PY, Chou CY, Chuang YW, Lee BJ, Kao CH. Risk factors associated with end-stage renal disease (ESRD) in patients with atherosclerotic renal artery stenosis: a nationwide population-based analysis. Medicine (Baltimore) 2015; 94:e912. [PMID: 26020404 PMCID: PMC4616421 DOI: 10.1097/md.0000000000000912] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
The aim of this study was to investigate the risk factors associated with end-stage renal disease (ESRD) in patients with atherosclerotic renal artery stenosis (ARAS). Information about the study participants was extracted from the National Health Insurance Research Database of Taiwan for the years 1999 through 2011. We conducted this retrospective cohort study of patients with ARAS to identify the potential risk factors associated with long-term renal outcomes. A total of 2184 patients with ARAS were enrolled, of whom 840 had ESRD and were classified as the study group, and 1344 patients who were without ESRD were included in the comparison cohort. After adjusting for related variables, univariable, and multivariable logistic regression analysis showed that ESRD was associated with higher Charlson-comorbidity index (CCI) score (adjusted odds ratio [OR] = 6.78, 95% CI = 4.59-10.0 for CCI = 2; adjusted OR = 20.0, 95% CI = 13.7-29.2 for CCI ≥3), diabetes (adjusted OR = 1.55, 95% CI = 1.24-1.93), hypertension (adjusted OR = 3.66, 95% CI = 2.36-5.66), and age 20 to 49-years old (adjusted OR = 2.14, 95% CI = 1.51-3.03). Moreover, our data showed that renal artery revascularization (RAR) was significantly associated with a lower risk of ESRD in ARAS patients (crude OR = 0.64, 95% CI = 0.50-0.84). Our study is the first to disclose that CCI score was significantly associated with the risk of ESRD in ARAS patients, and comorbid diseases including diabetes mellitus and hypertension significantly affect renal outcomes in patients with ARAS. Of note, our data showed that renal artery revascularization was associated with a lower risk of ESRD in ARAS patients in long-term follow-up.
Collapse
Affiliation(s)
- Tung-Min Yu
- From the Division of Nephrology, Taichung Veterans General Hospital (T-MY, Y-WC); Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung (T-MY, C-YC, C-HK); Division of Pediatric, Zhong-Xing Branch, Taipei City Hospital, Taipei (C-SS); Management Office for Health Data, China Medical University Hospital, Taichung (C-LL); College of Medicine, China Medical University, Taichung (C-LL, C-YC); Department of Radiology, Taichung Veterans General Hospital (P-YC); Department of Critical Care, Taichung Veterans General Hospital (C-YW, B-JL); and Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan (C-HK)
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Zelmanovitz T, Gerchman F, Balthazar APS, Thomazelli FCS, Matos JD, Canani LH. Diabetic nephropathy. Diabetol Metab Syndr 2009; 1:10. [PMID: 19825147 PMCID: PMC2761852 DOI: 10.1186/1758-5996-1-10] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2009] [Accepted: 09/21/2009] [Indexed: 12/21/2022] Open
Abstract
Diabetic nephropathy is the leading cause of chronic renal disease and a major cause of cardiovascular mortality. Diabetic nephropathy has been categorized into stages: microalbuminuria and macroalbuminuria. The cut-off values of micro- and macroalbuminuria are arbitrary and their values have been questioned. Subjects in the upper-normal range of albuminuria seem to be at high risk of progression to micro- or macroalbuminuria and they also had a higher blood pressure than normoalbuminuric subjects in the lower normoalbuminuria range. Diabetic nephropathy screening is made by measuring albumin in spot urine. If abnormal, it should be confirmed in two out three samples collected in a three to six-months interval. Additionally, it is recommended that glomerular filtration rate be routinely estimated for appropriate screening of nephropathy, because some patients present a decreased glomerular filtration rate when urine albumin values are in the normal range. The two main risk factors for diabetic nephropathy are hyperglycemia and arterial hypertension, but the genetic susceptibility in both type 1 and type 2 diabetes is of great importance. Other risk factors are smoking, dyslipidemia, proteinuria, glomerular hyperfiltration and dietary factors. Nephropathy is pathologically characterized in individuals with type 1 diabetes by thickening of glomerular and tubular basal membranes, with progressive mesangial expansion (diffuse or nodular) leading to progressive reduction of glomerular filtration surface. Concurrent interstitial morphological alterations and hyalinization of afferent and efferent glomerular arterioles also occur. Podocytes abnormalities also appear to be involved in the glomerulosclerosis process. In patients with type 2 diabetes, renal lesions are heterogeneous and more complex than in individuals with type 1 diabetes. Treatment of diabetic nephropathy is based on a multiple risk factor approach, and the goal is retarding the development or progression of the disease and to decrease the subject's increased risk of cardiovascular disease. Achieving the best metabolic control, treating hypertension (<130/80 mmHg) and dyslipidemia (LDL cholesterol <100 mg/dl), using drugs that block the renin-angiotensin-aldosterone system, are effective strategies for preventing the development of microalbuminuria, delaying the progression to more advanced stages of nephropathy and reducing cardiovascular mortality in patients with diabetes.
Collapse
Affiliation(s)
- Themis Zelmanovitz
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- Universidade Federal do Rio Grande do Sul, Brazil
| | - Fernando Gerchman
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | | | | | | | - Luís H Canani
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- Universidade Federal do Rio Grande do Sul, Brazil
| |
Collapse
|
3
|
Abstract
Patients with diabetes mellitus are at increased risk for developing peripheral vascular disease and renal artery stenosis (RAS). Furthermore, in diabetic patients the progression of renal atherosclerotic disease toward critical stenosis or occlusion occurs more frequently than in their nondiabetic counterparts. Consequently, clinicians must carry a high level of suspicion for detecting RAS in diabetic patients, particularly those with established coronary and/or peripheral atherosclerotic disease and compromised renal function. In this group of patients early detection of this condition, preferably with a noninvasive diagnostic test, is very important to plan revascularization therapy. In nondiabetic patients, several studies have demonstrated that catheter-based revascularization therapy may arrest or revert renal dysfunction in patients with RAS. Although still the subject of debate, a recent study has shown that in diabetic patients with RAS and impaired renal function, revascularization therapy with endovascular stents has a positive impact in the progression of renal dysfunction.
Collapse
Affiliation(s)
- Jose A Silva
- Tchefuncte Cardiovascular Associates and TCA Research, 101 East Fairway Drive, Suite 504, Covington, LA 70433, USA.
| |
Collapse
|
4
|
Rajashekar A, Perazella MA, Crowley S. Systemic Diseases with Renal Manifestations. Prim Care 2008; 35:297-328, vi-vii. [DOI: 10.1016/j.pop.2008.01.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Gross JL, Silveiro SP, Canani LH, Friedman R, Leitão CB, Azevedo MJD. Nefropatia diabética e doença cardíaca. ACTA ACUST UNITED AC 2007; 51:244-56. [PMID: 17505631 DOI: 10.1590/s0004-27302007000200013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2007] [Accepted: 01/15/2007] [Indexed: 01/19/2023]
Abstract
Pacientes em diferentes estágios de nefropatia diabética (ND) apresentam freqüentemente comprometimento cardíaco expresso por isquemia miocárdica e/ou cardiomiopatia diabética. Estas alterações já estão presentes em estágios iniciais da ND e provavelmente mesmo antes de a excreção urinária de albumina (EUA) atingir níveis tradicionalmente diagnósticos de microalbuminúria. As alterações cardíacas são responsáveis por uma proporção significativa de mortes nos pacientes com ND e podem ser reduzidas através de intervenção nos múltiplos fatores de risco cardiovascular encontrados nesses pacientes. A avaliação de doença cardíaca deve idealmente ser realizada em todos os pacientes com qualquer grau de ND através de métodos específicos para detectar isquemia e disfunção miocárdica, além do emprego rotineiro da monitorização ambulatorial da pressão arterial em 24 h. Em pacientes com aterosclerose avançada também devem ser avaliadas outras artérias (carótidas, aorta, renais). O tratamento rigoroso da hipertensão arterial, o uso de fármacos cardioprotetores, o tratamento da dislipidemia e da anemia, assim como o emprego de medicamentos anti-plaquetários, poderão reduzir a elevada mortalidade cardiovascular na ND.
Collapse
Affiliation(s)
- Jorge Luiz Gross
- Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, RS, Brazil
| | | | | | | | | | | |
Collapse
|
6
|
Silva JA, Potluri S, White CJ, Collins TJ, Jenkins JS, Subramanian R, Ramee SR. Diabetes mellitus does not preclude stabilization or improvement of renal function after stent revascularization in patients with kidney insufficiency and renal artery stenosis. Catheter Cardiovasc Interv 2007; 69:902-7. [PMID: 17192944 DOI: 10.1002/ccd.20980] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To assess the impact of stent revascularization on the renal function of diabetic and nondiabetic patients with renal insufficiency. BACKGROUND Renal artery revascularization has been shown to stabilize or improve renal function in patients with significant renal artery stenosis and impaired renal function. However, some studies have suggested negligible or no benefit of renal function in diabetic patients with the same condition. METHODS We retrospectively compared data from 50 consecutive patients undergoing renal artery stent placement with renal insufficiency (serum creatinine > or = 1.5-4.0 mg/dl) and global ischemia (bilateral or solitary [single] kidney renal artery stenosis) There were 17 diabetic (DM) and 33 nondiabetic (NDM) patients. The endpoints included the follow-up measurements of renal function, blood pressure, and number of antihypertensive medications. RESULTS After stent placement, at a mean follow-up of 42 +/- 18 months (range: 6-62 months), 79% NDM (N = 26), and 76% DM patients (N = 13) (P = NS) had improvement in the slope of the reciprocal of creatinine (1/SCr), indicating a beneficial effect in renal function in many patients. CONCLUSION Renal artery stent placement appears to be equally beneficial in preserving renal function in DM and NDM patients with ischemic nephropathy and global renal ischemia.
Collapse
Affiliation(s)
- Jose A Silva
- Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA.
| | | | | | | | | | | | | |
Collapse
|
7
|
Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005; 56:173-89. [PMID: 15793607 DOI: 10.1177/000331970505600208] [Citation(s) in RCA: 97] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Diabetes mellitus (DM) is associated with an increased incidence of cardiovascular events and microvascular complications. These complications contribute to the morbidity and mortality associated with DM. There is increasing evidence supporting a role for matrix metalloproteinases (MMPs) and their inhibitors (tissue inhibitors of matrix metalloproteinases - TIMPs) in the atherosclerotic process. However, the relationship between MMPs/TIMPs and diabetic angiopathy is less well defined. Hyperglycemia directly or indirectly (eg, via oxidative stress or advanced glycation products) increases MMP expression and activity. These changes are associated with histologic alterations in large vessels. On the other hand, low proteolytic activity of MMPs contributes to diabetic nephropathy. Within atherosclerotic plaques an imbalance between MMPs and TIMPs may induce matrix degradation, resulting in an increased risk of plaque rupture. Furthermore, because MMPs enhance blood coagulability, MMPs and TIMPs may play a role in acute thrombotic occlusion of vessels and consequent cardiovascular events. Some drugs can inhibit MMP activity. However, the precise mechanisms involved are still not defined. Further research is required to demonstrate the causative relationship between MMPs/TIMPs and diabetic atherosclerosis. It also remains to be established if the long-term administration of MMP inhibitors can prevent acute cardiovascular events.
Collapse
Affiliation(s)
- Nikolaos P Kadoglou
- Department of Vascular Surgery, Athens University Medical School, Athens, Greece.
| | | | | | | |
Collapse
|
8
|
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28:164-76. [PMID: 15616252 DOI: 10.2337/diacare.28.1.164] [Citation(s) in RCA: 1049] [Impact Index Per Article: 55.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects approximately 40% of type 1 and type 2 diabetic patients. It increases the risk of death, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE) in the absence of other renal diseases. Diabetic nephropathy is categorized into stages: microalbuminuria (UAE >20 microg/min and < or =199 microg/min) and macroalbuminuria (UAE > or =200 microg/min). Hyperglycemia, increased blood pressure levels, and genetic predisposition are the main risk factors for the development of diabetic nephropathy. Elevated serum lipids, smoking habits, and the amount and origin of dietary protein also seem to play a role as risk factors. Screening for microalbuminuria should be performed yearly, starting 5 years after diagnosis in type 1 diabetes or earlier in the presence of puberty or poor metabolic control. In patients with type 2 diabetes, screening should be performed at diagnosis and yearly thereafter. Patients with micro- and macroalbuminuria should undergo an evaluation regarding the presence of comorbid associations, especially retinopathy and macrovascular disease. Achieving the best metabolic control (A1c <7%), treating hypertension (<130/80 mmHg or <125/75 mmHg if proteinuria >1.0 g/24 h and increased serum creatinine), using drugs with blockade effect on the renin-angiotensin-aldosterone system, and treating dyslipidemia (LDL cholesterol <100 mg/dl) are effective strategies for preventing the development of microalbuminuria, in delaying the progression to more advanced stages of nephropathy and in reducing cardiovascular mortality in patients with type 1 and type 2 diabetes.
Collapse
Affiliation(s)
- Jorge L Gross
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
| | | | | | | | | | | |
Collapse
|
9
|
Abstract
As the epidemic of diabetes spreads so does the number of patients at risk for developing diabetic nephropathy, which occurs in 20% to 40% of all diabetic patients. Indeed, diabetes is the most common cause of end-stage renal disease (ESRD) in the United States, accounting for > 40% of patients starting renal replacement therapy each year. Unfortunately, the outcome for diabetic patients with ESRD is worse than that for nondiabetic patients because of comorbid conditions in the diabetic population. However, with early and intensive blood glucose and blood pressure control--including the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers--the development and progression of diabetic kidney disease can be slowed.
Collapse
Affiliation(s)
- Ralph Rabkin
- Department of Medicine, Division of Nephrology, Stanford University, Stanford, California, USA
| |
Collapse
|
10
|
Aliciguzel Y, Ozen I, Aslan M, Karayalcin U. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. ACTA ACUST UNITED AC 2003; 142:172-7. [PMID: 14532905 DOI: 10.1016/s0022-2143(03)00110-0] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Oxidative stress is an important pathogenic constituent in diabetic endothelial dysfunction. The aim of this study was to investigate whether an increase in oxidative stress related to xanthine oxidoreductase occurs in diabetes. Liver, brain, heart, and kidney xanthine oxidase (XO), xanthine dehydrogenase (XDH), antioxidant enzymes (glutathione peroxidase, superoxide dismutase, catalase), and nitrite levels were measured in control and early and late diabetic rat models. Although diabetes had no impact on liver XO and XDH activity, XDH activity in heart, kidney, and brain was significantly greater in late diabetic rats than in controls. Selenium glutathione peroxidase (GPx) activity was found to be lower in the liver, brain, kidney, and heart of late diabetic rats than in controls. The measured decrease in selenium GPx activity was also observed in early diabetic heart, kidney, and brain. No significant change was observed in liver, brain, and kidney copper/zinc superoxide dismutase (Cu/Zn SOD) activity in early and late diabetic rat models compared with that in controls, whereas heart Cu/Zn SOD activity was significantly decreased in both early and late diabetic rats. Liver and brain catalase activity remained similar among the different experimental groups, whereas increased heart and kidney catalase activity was observed in both early and late diabetic rats. Liver, kidney, and brain nitrite levels were found to be increased in early diabetic rat models compared with those in controls. These data suggest that the increased XDH and decreased selenium GPx activity observed in the later stages of diabetes leads to enhanced oxidative stress in the heart, kidney, and brain, resulting in secondary organ damage associated with the disease.
Collapse
Affiliation(s)
- Yakup Aliciguzel
- Department of Biochemistry, Akdeniz University Medical School, Antalya, Turkey.
| | | | | | | |
Collapse
|
11
|
Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Curr Opin Nephrol Hypertens 2003; 12:317-22. [PMID: 12698072 DOI: 10.1097/00041552-200305000-00015] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW To summarize recent trends in the prevalence of nephropathy due to diabetes and to assess the causes of these changes. Such analysis may influence our strategy to reduce the increasing numbers of cases. RECENT FINDINGS Registry data show a progressive increase in the number of cases of nephropathy due to type 2 diabetes such that diabetes is now the leading cause of end-stage renal failure. Despite the increasing incidence of type 1 diabetes, European data indicate the numbers of type 1 patients going on to dialysis are stable. The increase in the prevalence of type 2 diabetes, which in itself is related to increasing levels of obesity, is a major factor but the increase in end-stage renal failure is disproportionately greater. Other factors are therefore important such as earlier development of diabetes and better prevention of coronary events. Similar changes are occurring worldwide. Clinical predictors and genetic markers are being studied. SUMMARY More active management of proteinuric type 2 diabetic patients is required to achieve the demanding targets recommended on the basis of clinical trial data. However, the figures suggest that only widespread application of public health measures aimed at the epidemic of type 2 diabetes itself will prevent further rapid escalation of the numbers of type 2 patients reaching end-stage renal failure.
Collapse
Affiliation(s)
- John N Harvey
- University of Wales College of Medicine, Wrexham Academmic Unit, Maelor Hospital, Wrexham, UK.
| |
Collapse
|
12
|
Current literature in diabetes. Diabetes Metab Res Rev 2003; 19:164-71. [PMID: 12673786 DOI: 10.1002/dmrr.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|